Introduction {#s1}
============

The concept of direct transduction of simple chemical changes into distinct physiological effects was definitively established by the elucidation of the mechanisms of action of nuclear receptors (NRs), which interact with the genome and directly regulate gene transcription in response to chemical ligands like lipophilic hormones, vitamins, various metabolites, and synthetic drugs ([@B1], [@B2]). The discovery of this ligand-dependent response system ignited a new era in molecular endocrinology. Of the 48 human NRs, there are a few for which appropriate endogenous ligands have yet to be identified and thus are termed orphan receptors ([@B3], [@B4]). Estrogen-related receptors (ERRs) were the first orphan NRs identified and this sub-family of NRs now consist of ERRα, ERRβ, and ERRγ ([@B5], [@B6]). Although ERRs do share sequence similarities with estrogen receptors (ERs), they are not activated by estrogens, making the name "estrogen-related receptors" inappropriate or unfortunately even misleading. As the ERRs have been established as major regulators of energy metabolism ([@B7]), a more suitable acronym for ERR would be "energy-related receptors." While many orphan NRs were eventually "de-orphanized," the ERRs remain to this date orphans ([@B4]). In this review, our focus will be mainly on the most-studied member of the ERR subfamily, ERRα, specifically in the transcriptional control of hepatocellular functions as significant efforts in the last decade have been made toward unraveling the role of this receptor in liver health and disease.

Given the lack of ligands to directly regulate ERRα activity, initial study of the transcriptome and cellular pathways regulated by ERRα was hampered as compared with other NRs. However, integration of gene expression profiles and genome-wide chromatin immunoprecipitation (ChIP)-based studies together with in-depth phenotypic analyses of ERRα-null mice then facilitated the studies of ERRα cellular functions and rapidly advanced our understanding and appreciation of ERRα as a major transcriptional regulator of mitochondrial function and metabolism. While reviews discussed the primary functions of ERRα in diverse contexts ([@B8]--[@B11]), its pivotal role in liver homeostasis deserves an independent review. The liver is an essential metabolic organ that governs whole-body energy metabolism and dysregulation of hepatic homeostasis is a major contributor to the metabolic syndrome including insulin resistance, non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. It has been shown that liver energy metabolism is under strict regulation by numerous NRs as well as their coregulators, whose activities are regulated by upstream signals like insulin, glucagon as well as other metabolic hormones ([@B12], [@B13]). Herein, we will provide a brief overview of ERRα, its role as a sensor of intrinsic and environmental cues, highlight ERRα-driven hepatic transcriptional gene networks that underscore its key role in energy homeostasis and discuss the potential benefits of modulating ERRα activity to prevent and/or treat liver metabolic dysfunction and diseases.

The Orphan Nuclear Receptor ERRα {#s2}
================================

Structure and Function
----------------------

The three ERRs comprise the NR3B subgroup, which belongs to the larger NR3 subfamily of classic steroid receptors, including the ERs, androgen, progesterone, mineralocorticoid, and glucocorticoid receptors ([@B14], [@B15]). ERRα (NR3B1, *Esrra*) was initially discovered in 1988 in a screen designed to identify novel steroid hormone receptors closely related to human ERα and consequently named ERRα ([@B5]). However, it turned out that this new receptor did not bind natural estrogens, or other known steroid hormones as well as their derivatives, and as such it was recognized as the first orphan nuclear receptor. ERRβ (NR3B2, *Esrrb*) was identified by using ERRα cDNA as a probe ([@B5]) while ERRγ (NR3B3, *Esrrg*) was discovered a decade later ([@B16]). The expression of ERRα is ubiquitous and is elevated in metabolically active tissues such as the heart, kidneys, intestine, skeletal muscle, brown adipose tissue (BAT) and liver. Generally, the expression of ERRα is more abundant than the other two ERR members ([@B7], [@B10]).

ERRα possesses the characteristic structural features typical to NRs, including a non-conserved amino-terminal domain (NTD), a central zinc finger DNA-binding domain (DBD), and a functional C-terminal ligand-binding domain (LBD) ([@B15]). Notably, the three ERRs share considerable structural relatedness in their NTDs, which is typically poorly conserved among NRs. For example, ERRα and ERRγ both contain a functional phospho-sumoyl switch motif in this domain ([@B17], [@B18]), indicating an important role of the NTD in the regulation of ERR transcriptional activities. The ERRs regulate gene expression via binding to a specific DNA sequence in regulatory regions located in the promoter or at a distal site from the transcriptional start site of a target gene, referred to as the ERR element (ERRE). By using an unbiased binding site selection approach, the binding motif for the ERRs was defined as TCAAGGTCA ([@B19]). This motif was validated to serve as the main ERR binding site *in vivo* by bioinformatics analysis of a large set of ERR target promoters identified in different cell types through ChIP coupled with genomic DNA array technology (ChIP-on-chip) ([@B20]--[@B22]) and later confirmed by ChIP-seq studies ([@B23]--[@B26]). The DBD sequence of ERRα is highly conserved with that of ERRβ and γ, therefore most if not all ERR target genes can be targeted by all three ERR isoforms ([@B20], [@B26]). Indeed, the ERRs have the ability to bind to the ERRE not only as a monomer or homodimer but also as heterodimer composed of two distinct ERR isoforms ([@B20], [@B27]--[@B29]). The LBD of the ERRs contain a well-conserved activation function-2 (AF-2 helix) motif that is positioned in the active configuration even in the absence of a ligand ([@B30], [@B31]). Thus, the ERRs display significant constitutive transcriptional activity that is dependent on the interaction with coregulators, which are often considered as protein ligands for the ERRs ([@B32]).

Regulation of ERRα Activity by Transcriptional Co-regulators
------------------------------------------------------------

ERRα activates or represses gene expression in response to different cellular signals, being highly dependent on the presence of its co-regulators in specific tissues or cultured cell lines. The peroxisome proliferator-activated receptor γ (PPARγ)-coactivator 1 α (PGC-1α) is the most notable and potent coactivator of ERRα ([@B33]--[@B37]). PGC-1α has been shown to play an essential role in mitochondrial biogenesis, oxidative phosphorylation (OXPHOS), fatty acid β-oxidation (FAO), adaptive thermogenesis, glucose uptake, glycolysis, hepatic gluconeogenesis, ketogenesis, and circadian activity via selectively interacting with and co-activating diverse transcription factors ([@B38], [@B39]). PGC-1α and ERRα display similar expression patterns, being expressed in tissues reliant on oxidative metabolism for elevated energy requirements, such as the heart, skeletal muscle, BAT and liver ([@B19], [@B40], [@B41]). Indeed, PGC-1α, PGC-1β, and ERRα have shown a functional co-dependency in the control of vast metabolic gene networks in numerous tissues ([@B24], [@B42]--[@B46]). The ERRα/PGC-1α functional complexes were first identified in a yeast two-hybrid screen of a cardiac cDNA library ([@B33]). Prior to this discovery, *Acadm* was identified as the first *bona fide* ERRα target gene, encoding medium-chain acyl coenzyme A (MCAD), which catalyzes the initial step in mitochondrial FAO ([@B19], [@B40]). Moreover, ERRα binds to a distal enhancer of *Ppargc1a* to drive its expression ([@B47]). In turn, expression of PGC-1α coactivates ERRα, forming a feed-forward loop to promote the expression of metabolic genes ([@B34], [@B36], [@B47], [@B48]). Interestingly, *in vitro* binding experiments demonstrated that ERRα binds PGC-1α via a leucine-rich motif which is specifically recognized by the ERRs ([@B33], [@B49]). The utilization by the ERRs of a distinct PGC-1α interaction interface offers the opportunity to regulate ERR/PGC-1α signaling via post-translational modifications (PTMs) of either partner.

The NR corepressor 1 (NCoR1) is a well-characterized and ubiquitously expressed corepressor. It regulates gene transcription by forming a large protein complex in which the chromatin modifying enzyme histone deacetylase 3 (HDAC3) is a core component ([@B50]). Current studies propose a yin-yang relationship between PGC-1α and NCoR1 that confers opposing effects on the transcriptional activity of ERRα ([@B51], [@B52]). Indeed, global gene expression analysis revealed a high overlap between the effects of PGC-1α overexpression and NCoR1 deletion on metabolic genes in muscle, and consistent with this, the stimulatory effect of PGC-1α on OXPHOS gene expression specifically counteracts NCoR1-mediated repression of ERRα. The use of a common binding pocket by different coactivators and corepressors suggests a critical regulation of this cofactor exchange ([@B53]). NCoR1 is a basal corepressor, thus it seems to repress ERRα under basal conditions and is exchanged with coactivators upon physiological stimuli such as cold exposure and exercise ([@B51]). The homeodomain-containing protein PROX1 can also form an inhibitory complex with ERRα and PGC-1α ([@B22]). PROX1 was shown to occupy the promoters of metabolic genes on a genome-wide scale and bind to \~40% of ERRα target genes ([@B22]). Furthermore, ERRα transcriptional activity can atypically be repressed or activated by the NR interacting protein 140 (RIP140) ([@B54]--[@B56]). RIP140 has been shown to repress several genes involved in glucose and lipid metabolism. Also, RIP140 expression is up-regulated by ERRα during adipogenesis suggesting a role for the RIP140/ERRα complex in maintaining energy homeostasis in adipocytes ([@B57]--[@B59]). In summary, the shift between different ERRα-regulated pathways in response to physiological and metabolic cues is likely facilitated through interactions with distinct coregulators.

Regulation of ERRα Activity by Post-transcriptional and Post-translational Control Mechanisms
---------------------------------------------------------------------------------------------

The activity of ERRα is dynamically modulated post-transcriptionally by microRNAs (miRNAs). miRNAs are endogenous small non-coding RNAs of \~22 nucleotides in length, which have recently emerged as important regulators of gene expression in many diseases by targeting messenger RNAs (mRNAs) for degradation or translational repression ([@B60], [@B61]). *ESRRA* is a direct target of miRNA-137 and miR-125a ([@B62]--[@B65]). miRNA-137-mediated *ESRRA* mRNA degradation contributes to the impaired proliferative and migratory capacity of breast cancer (BCa) cells as well as that of placenta trophoblast cells through reduced expression of the ERRα-regulated gene *WNT11*. miR-125a, by targeting *ESRRA* mRNA, reduces the proliferation and invasion of oral squamous cell carcinoma cells. miR-125a also negatively regulates porcine pre-adipocyte differentiation, partly via suppressing ERRα action. The activity of ERRα is also regulated by PTMs including ubiquitination, phosphorylation, sumoylation and acetylation. The protein level of ERRα is under the control of the ubiquitin-proteasome system (UPS). Parkin, an E3-ubiquitin (Ub) ligase whose mutations cause Parkinson\'s disease, reduces dopamine toxicity and oxidative stress by promoting ERRα ubiquitination and degradation, and thus abolishing ERRα-mediated activation of monoamine oxidase (MAO) promoters ([@B66]). Furthermore, mTOR was shown to positively regulate ERRα protein stability and activity via transcriptional control of the UPS involving repression of the genes *Stub1* and *Ubb* ([@B23]). ERRα is also a phosphoprotein that is phosphorylated on multiple sites. Barry et al. first reported that epidermal growth factor (EGF) treatment of MCF-7 cells enhanced ERRα phosphorylation, DNA binding, homodimerization, interaction with PGC-1α and transcriptional activity by activating protein kinase Cδ (PKCδ) ([@B67]). Ariazi et al. subsequently found that ERRα was phosphorylated *in vitro* by MAPK and AKT proteins, downstream kinases of the EGFR/ErbB2 (HER-2) signaling pathway, and that ErbB2 signaling elevated ERRα phosphorylation levels and transcriptional activity in BCa ([@B68]). Furthermore, cAMP has been shown to increase ERRα phosphorylation and nuclear localization either via the cAMP-PKA signaling cascade in lung type II cells ([@B69]) or by the cAMP-PI3K-ERK signaling pathway in prostate stromal cells ([@B70]). Serine residues 19 and 22 of ERRα serve as the major sites of phosphorylation in BCa cells and phosphorylation at serine 19 represses ERRα transcriptional activity via its effects on sumoylation of ERRα on lysine 14 ([@B17], [@B18]). Moreover, the affinity of ERRα for binding to ERREs is affected by a dynamic acetylation/deacetylation switch of four highly-conserved lysine residues within the DBD mediated by the acetyltransferase p300 coactivator associated factor (PCAF) and deacetylases, HDAC8 and sirtuin 1 homolog (SIRT1) ([@B71]). It must also be noted that ERRα activity can also be influenced by PTMs of its coregulators. For example, insulin induces the phosphorylation of NCoR1 on serine 1460 via AKT activation and this PTM selectively favors the interaction between NCoR1 and ERRα, thus repressing ERRα target genes involved in oxidative metabolism and liver fatty acid catabolism ([@B72]). Another example is HDAC3, which usually acts as a transcriptional corepressor together with NCoR1. However, HDAC3 activates ERRα in BAT by de-acetylating PGC1α, promoting the transcription of *Ucp1* and OXPHOS genes to ensure survival upon exposure to prolonged cold exposure ([@B47]). Together, microRNA targeting of *ESRRA* mRNA and PTMs of ERRα and its coregulators (summarized in [Table 1](#T1){ref-type="table"}) demonstrate that the ligand-independent transcriptional activity of ERRα can be dynamically and tightly regulated in response to changing metabolic signals.

###### 

Known regulators of ERRα transcriptional activity.

  **Factor**   **Mechanism**                               **Effect on ERRα activity**          **References**
  ------------ ------------------------------------------- ------------------------------------ ----------------------------------
  PGC-1α       Coactivator                                 Increases                            ([@B33]--[@B35], [@B37])
  PGC-1β       Coactivator                                 Increases                            ([@B32], [@B42], [@B46], [@B73])
  SRC          Coactivator                                 Increases                            ([@B74], [@B75])
  PNRC2        Coactivator                                 Increases                            ([@B76])
  NCoR1        Corepressor                                 Represses                            ([@B51], [@B52], [@B72])
  PROX1        Corepressor                                 Represses                            ([@B22])
  RIP140       Corepressor/coactivator                     Represses/increases                  ([@B54]--[@B56])
  miR-137      Targets 3′UTR of *ESRRA*                    Represses                            ([@B62], [@B63])
  miR-125a     Targets 3′UTR of *ESRRA*                    Represses                            ([@B64], [@B65])
  Parkin       Ubiquitination                              Represses                            ([@B66])
  mTOR         UPS repression                              Increases                            ([@B23])
  PCAF         Acetylation                                 Represses                            ([@B71])
  HDAC8        Deacetylation                               Enhances ERRα DNA binding affinity   ([@B71])
  SIRT1        Deacetylation                               Enhances ERRα DNA binding affinity   ([@B71])
  PIASy        Sumoylation (Lys^14^ and Lys^403^)          Represses                            ([@B17], [@B18])
  Kinase       Phosphorylation (Ser^19^)                   Represses                            ([@B17], [@B18])
  PKCδ         Phosphorylation                             Enhances ERRα DNA binding affinity   ([@B67])
  MAPK         Phosphorylation                             Increases                            ([@B68])
  AKT          Phosphorylation                             Increases                            ([@B68])
  PKA          Phosphorylation and nuclear translocation   Increases                            ([@B69])
  PI3K-ERK     Phosphorylation and nuclear translocation   Increases                            ([@B70])
  HDAC3        Deacetylation of PGC1α                      Increases                            ([@B47])

Role of ERRα in Adaptation to Energy Demands and Environmental Cues {#s3}
===================================================================

Dynamic regulation of gene networks by ERRα is required for the bioenergetic and functional adaptation to environmental stresses. External stimuli such as cold exposure upregulates the expression of ERRα as well as its coactivator PGC-1α in BAT and skeletal muscle of mice ([@B35], [@B47]), promoting thermogenesis through mitochondrial OXPHOS to adapt to cold environments. ERRα-null mice are unable to maintain body temperature in response to cold exposure because of a failure of mitochondrial biogenesis and oxidative capacity ([@B77], [@B78]). ERRα expression is also stimulated by exercise in a pattern parallel to that of PGC-1α in animal models and in humans ([@B79]--[@B81]). Accordingly, ERRα-null mice are hypoactive and exercise intolerant because of a reduced basal metabolic oxidative capacity ([@B82]--[@B84]). Moreover, the molecular clock serves as another input signal modulating ERRα levels in a circadian manner in tissues including liver and WAT ([@B84]--[@B87]). Furthermore, ERRα adapts to nutritional challenges such as increased intake of a lipid-rich diet or cycles of nutrient deprivation and availability by modulating metabolic gene and metabolite levels ([@B88], [@B89]). Rapamycin treatment, which is known to mimic amino-acid-like starvation, as well as glucose and amino acids deprivation also affect ERRα protein stability and transcriptional networks ([@B23]).

ERRα-Dependent Transcriptional Networks {#s4}
=======================================

Given the lack of a natural ligand or high affinity pharmacological agent that can activate ERRα, identification of biological pathways modulated by ERRα is usually achieved by overexpression of PGC-1α or ERRα expression itself followed by gene expression studies and bioinformatics analyses. Genetic deletion or ERRα knock-down experiments have also been applied to elucidate ERRα-mediated changes in transcriptomes. One common problem of these perturbation assays is that the identification of gene expression profiles cannot easily differentiate between primary and secondary targets of ERRα. The initial characterization of direct ERRα target genes was based on identifying ERRα binding sites through manual inspection and functional analyses of promoter regions of ERRα-responsive genes. Although inefficient, integration of the above approaches helped to uncover multiple ERRα target genes and implicated ERRα in the regulation of FAO ([@B19], [@B40]), gluconeogenesis ([@B90]), lipid transport and uptake ([@B91]), as well as mitochondrial biogenesis and function ([@B34], [@B92], [@B93]). These ERRα targets were later validated by a series of genome-wide ChIP-based studies generated from the work of our laboratory ([@B20]--[@B23], [@B25], [@B42], [@B83]). ChIP-qPCR, ChIP-on-chip and ChIP-seq techniques have been improved and developed during the last decade, enabling high-confidence large-scale and genome-wide location analyses of NRs for target gene discovery ([@B94]). The characterization of comprehensive ERRα transcriptional gene networks stemmed from the work published by Dufour et al. with the first report of a genome-wide study of ERRα performed using ChIP-on-chip analyses on mouse heart ([@B20]). In the study by Charest-Marcotte et al., the use of ChIP-on-chip experiments on mouse liver led to the discovery of a genomic and functional relationship between ERRα and Prox1 ([@B22]). An important finding of this study was the discovery of the ERRα bioenergetic regulon, a cluster of functionally linked genes involved in the generation of energy from glucose. ERRα was found recruited to genes encoding virtually all enzymes involved in glycolysis, pyruvate metabolism, and the tricarboxylic acid (TCA) cycle aside the previously confirmed OXPHOS genes. Furthermore, by performing a comparative analysis of genome-wide binding of nuclear mTOR and ERRα by ChIP-seq, Chaveroux et al. revealed that mTOR is recruited to pol-III-transcribed genes to control mRNA translation and also to a large subset of pol-II-driven gene programs involved in UPS, insulin signaling, OXPHOS and fatty acid metabolism ([@B23]). Although this study showed that nuclear mTOR and ERRα co-binding to genomic loci were rare events, the two factors were found to co-regulate numerous genes implicated in the transcriptional regulation of common metabolic processes such as the TCA cycle and lipogenesis.

ERRα Gene Networks in the Liver {#s5}
===============================

Bioinformatics analysis of ERRα target genes identified from the mouse liver ChIP-seq analysis ([@B23]) corroborated the early finding that ERRα is a regulator of mitochondrial function and metabolism ([Figure 1](#F1){ref-type="fig"}). Word clouds illustrating the functional analysis of ERRα target genes using Gene Ontology (GO) cellular component, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Ingenuity Pathway Analysis (IPA) are shown with lower *p*-value associated terms displayed in larger font size. Genes targeted by ERRα are more significantly enriched for terms related to mitochondria and energy metabolism (e.g., mitochondrial dysfunction, OXPHOS) as well as diseases relating to metabolic dysfunction including NAFLD, insulin resistance, Alzheimer\'s and Parkinson\'s disease. Genetic or pharmacological manipulation of ERRα in rodent and cell-based studies have further characterized the genes and biological programs regulated by ERRα, establishing a major role of ERRα in liver homeostasis. A list of currently known genes found either activated or repressed by ERRα in hepatocytes in a context-specific manner with evidence for direct binding of ERRα within ± 20 kb of the TSS from ChIP-based studies is summarized in [Table S1](#SM1){ref-type="supplementary-material"} ([@B22], [@B23], [@B82], [@B84], [@B88], [@B90], [@B95]--[@B103]). A schematic of these direct ERRα-regulated genes associated to general biological processes are shown in [Figure 2](#F2){ref-type="fig"}. Notably, genes related to lipid metabolism are found mostly repressed by ERRα in stark contrast to genes associated with mitochondrial energy production found largely positively-regulated by ERRα.

![Bioinformatics analysis of direct ERRα target genes in mouse liver. Word clouds representing significantly overrepresented GO cellular component terms (top, green), KEGG pathways (right, blue) and the top 50 canonical pathways from Ingenuity Pathway Analysis (IPA) (left, purple) from the list of ERRα target genes with DNA binding events observed within ±10 kb of their transcription start sites as identified by ChIP-seq analysis ([@B23]). The size of the significant terms is reflective of their associated *p*-values whereby the most significant terms having lower *p*-values are displayed in larger font size.](fendo-10-00206-g0001){#F1}

![ERRα-regulated target genes and programs in liver cells. ERRα target genes ([@B104]) found transcriptionally regulated by ERRα in a positive (increased by ERRα, red) or negative (decreased by ERRα, blue) manner in hepatocytes from *in vivo* and *in vitro* studies involving genetic or pharmacological manipulation of ERRα activity are shown. Only ERRα-regulated genes having a high confidence for direct gene regulation by ERRα as determined by the presence of an ERRα-binding event within ±20 kb of the gene transcriptional start site were considered ([@B22], [@B23]). The genes, *Sdhb, Sdhc*, and *Sdhd* were associated to two biological programs. See also [Table S1](#SM1){ref-type="supplementary-material"} for more information.](fendo-10-00206-g0002){#F2}

ERRα Transcriptional Regulation of Glucose Metabolism
-----------------------------------------------------

The liver is a key organ in regulating glucose homeostasis especially during periods of fasting and refeeding. Several genes with established roles in glucose handling have been shown to be influenced by ERRα. For example, transcription of *PCK1* which encodes the rate-determining enzyme phosphoenolpyruvate carboxykinase (PEPCK) in gluconeogenesis is repressed by ERRα in hepatocytes ([@B90], [@B105]). Interestingly, ERRα represses gluconeogenesis by antagonizing the stimulatory effect of PGC-1α, possibly via inhibiting the recruitment of PGC-1α to the proximal regulatory region of *PCK1* ([@B90]). Indeed, expression of *Pck1* is significantly up-regulated in ERRα-null liver during the light phase of the circadian cycle at which time gluconeogenesis is active ([@B84]). However, no difference in the levels of *Pck1* mRNA between fasted wild-type and ERRα-null mice were observed ([@B90]). The expression of *PCK1* is under intense hormonal regulation and is induced during periods of fasting to maintain circulating glucose levels, which is inconsistent with the observation that hepatic expression of ERRα is also upregulated by fasting in normal mice ([@B105], [@B106]). The physiological role of ERRα in liver is to repress gluconeogenesis under fed conditions. Additionally, ERRα activation by PGC-1α induces the transcription of *Gck* encoding glucokinase (Gck) which phosphorylates glucose and participates in glucose utilization by stimulating glycolysis and glycogen synthesis in liver. *Gck* is also induced by insulin, which is partly mediated by ERRα ([@B107], [@B108]). Absence of ERRα in HepG2 cells impaired the reliance on glycolysis in the presence of inhibitors of mitochondrial function ([@B22]). These studies suggest that enhancing the transcriptional activity of ERRα in the fed state might have beneficial effects on glucose metabolism through suppression of hepatic gluconeogenesis as well as simultaneous activation of glycolysis and glycogen synthesis. Unexpectedly, despite the increased expression of gluconeogenic genes in the liver of fed ERRα null mice, blood glucose levels were normal in the fed state ([@B84], [@B90]), which might result from increased glucose oxidation in the absence of ERRα. Indeed, ERRα has been shown to inhibit glucose oxidation by transcriptionally activating *PDK4*, which encodes pyruvate dehydrogenase kinase 4 (PDK4), in muscle and hepatocytes ([@B37], [@B103], [@B109]). PDK4 inhibits cellular glucose utilization by phosphorylating and inactivating the pyruvate dehydrogenase complex (PDC), which allows pyruvate entry into the TCA cycle ([@B12]). Therefore, ERRα, via up-regulating the level of PDK4, supports a switch from glucose oxidation to FAO and ultimately leads to reduced glucose metabolism ([@B37], [@B103], [@B109]). Overall, ERRα seems to play multiple and contradictory roles in glucose metabolism.

ERRα Transcriptional Regulation of Lipid Metabolism
---------------------------------------------------

ERRα has be shown to play a fundamental role in lipid homeostasis. It is highly expressed in tissues that derive energy from fatty acid metabolism, likely contributing to the high basal levels of fatty acid utilization genes in these oxidative tissues ([@B110], [@B111]). Indeed, ERRα and MCAD are co-expressed in tissues with high energy needs. MCAD, whose expression levels are tightly regulated by tissue energy demands and dictate the rate of tissue FAO, catalyzes the first step in the mitochondrial oxidation of fatty acids ([@B19], [@B40], [@B77], [@B112]). Therefore, the initial finding that ERRα promotes the transcription of the MCAD gene (*Acadm*) ([@B19], [@B40]) and the further confirmation of the direct recruitment of ERRα at the *Acadm* promoter *in vivo* ([@B20], [@B77]) strongly suggests that ERRα activity increases fatty acid oxidation rates. However, gene expression profiling of adipose tissue from ERRα-null mice revealed an up-regulation of *Acadm* expression ([@B113]), whereas, analysis of adipose and muscle tissues from ERRα KO mice fed a high-fat diet (HFD) revealed no changes in the expression of this gene ([@B100]), suggesting that ERRα regulation of *Acadm* is nutrient-dependent. Genetic or pharmacological inhibition of ERRα leads to decreased lipid accumulation, reduced fat mass and resistance to HFD-induced obesity, partly because ERRα-null mice have a lower capacity for lipid absorption by the intestine ([@B84], [@B91], [@B100], [@B113], [@B114]). The intestine markedly contributes to total body FAO since it is essential for the uptake and transport of dietary fat, the first step in the energy chain ([@B91]). Microarray studies demonstrated that in addition to several down-regulated OXPHOS genes, the expression levels of a set of genes encoding proteins involved in lipid digestion and absorption were also altered in the ERRα-deficient intestine, including apolipoprotein (apo)A-IV ([@B91]). Furthermore, ERRα can stimulate adipogenesis via enhancing triglyceride (TG) accumulation and elevating expression of genes involved in lipid and energy metabolism in white adipose tissue (WAT), such as *Fasn*, the gene encoding fatty acid synthase ([@B115], [@B116]). Accordingly, ERRα-null mice display significantly decreased lipogenesis in WAT consistent with their leanness and decreased body weight gain in comparison to littermate controls chronically fed a HFD. The beneficial effects for loss of ERRα function in protection from HFD-induced body weight gain resulted also from a nearly 2-fold reduction in *de novo* hepatic lipogenesis ([@B88]). Although systemic ablation of ERRα protects mice from HFD-induced NAFLD, the presence of ERRα promotes the reversal of fasting-induced NAFLD by stimulating hepatic mitochondrial oxidative activity and halting WAT lipolysis during refeeding ([@B88]). Loss of ERRα prevented the transcriptional repression of the mouse *Fgf21* gene during the transition from a fasted to fed state, which is consistent with the impaired clearance of fasting-induced NAFLD in the absence of ERRα ([@B88]). Conversely, ablation of ERRα exacerbated rapamycin-induced NAFLD ([@B23]). Rapamycin treatment of ERRα-null mice reduces the expression of TCA enzymes in liver and enhances mRNA levels of genes involved in lipogenesis including *Acly, Fasn*, and *Scd1*. Consequently, citrate accumulates and is shuttled into the lipogenic pathway, promoting hepatic TG accumulation.

ERRα Transcriptional Regulation of the Mitochondrial TCA Cycle and Electron Transport Chain
-------------------------------------------------------------------------------------------

If the liver is central to energy homeostasis at the body level, mitochondria are the metabolic hubs at the cellular level. Consistent with [Figure 1](#F1){ref-type="fig"}, the GO cellular component analysis of hepatic ERRα target genes identified "mitochondria" as the top term, demonstrating that a primary function of ERRα is to regulate hepatic mitochondrial activity. It has been shown that overexpression of ERRα or PGC-1α enhances respiration capacity via promoting mitochondrial biogenesis and activity. On the other hand, loss of ERRα function leads to mitochondrial dysfunction and impaired ATP production partly by compromising the ability of PGC-1α to increase mitochondrial DNA content and to induce the expression of genes encoding mitochondrial proteins ([@B20], [@B34], [@B39], [@B102], [@B113], [@B117]--[@B119]). Functional genomic studies have identified ERRα as a comprehensive and genuine master regulator of the nuclear-encoded mitochondrial transcriptome. ERRα exerts its regulatory function via occupying the promoter regions of more than 700 genes encoding mitochondrial proteins, which are involved in all aspects of mitochondrial biogenesis and function ([@B11], [@B120]). No other transcription factor has been shown to control mitochondrial physiology and function as extensively. ChIP-seq analysis of ERRα binding in mouse liver showed that it binds to the regulatory regions of most genes encoding the enzymes involved in the TCA cycle, including: *Aco2, Idh3a, Idh3b, Sdha, Sdhb, Sdhc, Sdhd, Ogdh, Cs*, and *Fh1* ([@B23]). ERRα also occupies regulatory regions in the proximity of more than one hundred genes involved in the mitochondrial electron transport chain (ETC), including members of the NADH dehydrogenase complex, ubiquinol-cytochrome c reductases, several cytochrome c oxidase subunits, and the ATPase superfamily ([@B23]). Overall, as a master regulator of mitochondrial activity, ERRα positively regulates oxidative gene expression, aerobic respiration and ATP synthesis.

ERRα Transcriptional Regulation of Liver Functions Beyond Metabolism
--------------------------------------------------------------------

The liver has an architectural organization in which hepatocytes are in close proximity to immune cells and have immediate access to a vast network of blood vessels, enabling continuous and dynamic interactions between immune and metabolic responses ([@B12], [@B121]). In addition to its role in regulating energy metabolism, ERRα is also important in pathogen resistance and cancer development ([@B25], [@B42], [@B44]). Remarkably, ERRα plays a role in inflammation-related hepatocellular carcinoma (HCC) development. Global loss of ERRα activity promotes HCC following administration of the chemical carcinogen diethylnitrosamine (DEN) ([@B101]). Due to a deficiency in energy production, ERRα-null mice mediate DEN-induced cell death primarily by necrosis as opposed to apoptosis, an ATP-consuming process. In addition, the ERRα ChIP-seq study in mouse liver revealed that the gene *Nfkbia*, encoding the NF-κB suppressor IκBα, is a direct transcriptional target of ERRα. Further experiments confirmed that ERRα positively regulates IκBα expression in both hepatocytes and Kupffer cells. Thus, loss of ERRα resulted in enhanced NF-κB activity and subsequent cytokine gene activation in Kupffer cells, driving compensatory hepatocyte proliferation and HCC in response to DEN ([@B101]).

ERRα in Liver Health and Disease {#s6}
================================

Due to the complex network of coregulators and overlapping pathways as well as compensatory signaling mechanisms, the extent to which ERRα exerts its regulatory control *in vivo* may be difficult to predict. Although some of the anticipated effects and the consequent metabolic diseases caused by ERRα dysregulation may not necessarily be phenotypically manifested in the whole animal, ERRα clearly plays a central role in liver under both physiologic and pathologic conditions ([Figure 3](#F3){ref-type="fig"}).

![Current knowledge on the role of ERRα in liver physiology and pathology. Biological processes found either positively or negatively regulated by ERRα are shown. Under physiological conditions, ERRα can stimulate mitochondrial function and nutrient catabolism and repress *de novo* lipogenesis, gluconeogenesis and insulin signaling. Under pathological conditions, ERRα promotes the development of HFD-induced NAFLD on one hand and represses inflammation and protects from the development of rapamycin-induced NAFLD and liver cancer on the other.](fendo-10-00206-g0003){#F3}

The liver plays a crucial role in regulating whole-body energy metabolism via crosstalk with other tissues including skeletal muscle, adipose, gut, and the brain in response to different environmental cues such as the switch from fasting to feeding, acting as a hub to metabolically connect various tissues. Dysfunction of liver signal transduction and nutrient metabolism contributes to the progression of insulin resistance, type 2 diabetes and NAFLD ([@B12]). NAFLD can progress from hepatic steatosis to non-alcoholic steatohepatitis (NASH), and can further progress to a more severe state of liver cirrhosis and HCC ([@B122]).

ERRα in Insulin-Resistance and Diabetes
---------------------------------------

Insulin resistance, the condition in which a cell, tissue, or organism fails to respond appropriately to insulin, is a hallmark for the development of type 2 diabetes and a major contributor to the pathogenesis of NAFLD ([@B12], [@B104]). Obesity which is associated with chronic inflammation can also lead to insulin resistance ([@B121]). Liver, muscle, and adipose tissue are the organs most responsible for insulin-dependent glucose production and disposal. Insulin promotes glucose uptake into tissues such as muscle and adipose and simultaneously represses glucose production in the liver. Mitochondria, as the cellular powerhouse, is tightly associated with insulin sensitivity ([@B123]). A large body of data converges to support that transcriptional regulation plays a major role in the development of insulin resistance ([@B13], [@B104]). Previous findings have demonstrated reduced levels of ERRα-regulated genes in insulin-resistant humans ([@B34]), as well as the correlation between insulin sensitivity and ERRα mRNA expression in human adipose tissue ([@B124]). Furthermore, ERRα function has been shown to contribute to the development of insulin resistance in human diabetic muscle via down-regulating OXPHOS genes ([@B48], [@B125]), indicating the beneficial effects of enhancing ERRα activity in skeletal muscle on glucose uptake and handling. By contrast, in livers of patients with type 2 diabetes, OXPHOS genes are up-regulated and positively correlate with ERRα mRNA ([@B126]). Accordingly, hepatic insulin resistance is associated with increased mitochondrial respiration ([@B127], [@B128]). It has been proposed that in the context of hepatic insulin resistance, hyperinsulinemia increases hepatic lipogenesis and exacerbates fatty liver, in turn further increasing insulin resistance ([@B13]). Here we suggest that this vicious cycle can be reversed through antagonizing ERRα activity given that inhibition of ERRα decreases blood insulin levels, increases insulin sensitivity and protects animals from HFD-induced fatty liver ([@B88], [@B100], [@B114]). Together, there is compelling evidence to support a major role of ERRα as a transcriptional regulator of insulin action and changes in ERRα expression, DNA binding, PTMs, and cofactors recruitment could be linked to pathological changes in insulin resistance and diabetes through altering the expression of ERRα target genes.

ERRα in NAFLD {#s7}
=============

Exogenous lipids (diet), *de novo* lipogenesis and adipose tissue lipolysis are the three main sources of hepatic fatty acids (FAs). Excess accumulation of triglycerides in hepatocytes leads to NAFLD, the most common chronic liver disorder in Western countries. Many theories have been proposed for the pathogenesis of NAFLD, including the "two-hits," "multi-hits," and "distinct-hits" models. In common, these hypotheses suggest that insulin resistance and oxidative stress are associated with NAFLD ([@B129]). Remarkably, ERRα contributes to the development of NAFLD in a context-dependent manner. On one hand, absence of ERRα impairs the development of NAFLD in response to increased dietary fat intake ([@B88]). While the expression of ERRα- and PGC-1α-encoding genes are upregulated in WT mice under HFD, this response is likely an adaptive response to mitochondrial dysfunction ([@B130]). In light that ERRα deficiency increases the susceptibility of mice to rapamycin-induced NAFLD ([@B23]) and impairs the reversal of fasting-induced NAFLD during refeeding ([@B88]), inducing ERRα activity appears more beneficial to treat and reverse the instilled disease.

ERRα in Hepatocellular Carcinoma
--------------------------------

Chronic inflammation associated with NAFLD, together with obesity and mitochondrial reactive oxygen species (ROS) accumulation promote HCC development, the terminal stage of liver disease ([@B129]). During tumorigenesis, cells undergo a metabolic switch from mitochondrial OXPHOS to glycolysis, a phenomenon referred to as the Warburg effect ([@B131]). ERRα has been shown to influence tumorigenesis via substrate utilization, modulation of metabolic pathways and transcriptional regulation of key oncogenes ([@B9], [@B24], [@B25], [@B45], [@B132]). ERRα also contributes to ROS production and detoxification ([@B25], [@B42], [@B101]). Although the precise role of ERRα in the progression from NAFLD to HCC is unclear, loss of ERRα promotes carcinogen-induced liver cancer in mice despite the lower ROS levels observed due to the de-repression of an NF-κB-mediated inflammatory response ([@B101]).

Conclusions {#s8}
===========

Research findings presented in this review underscore a prominent role of ERRα in the regulation of hepatic homeostasis via direct modulation of an extensive range of metabolically-relevant genes and programs. Alongside a continued search for the natural endogenous ligand of ERRα, a key goal for the future is to exploit pharmaceuticals to modulate the transcriptional activity of ERRα to prevent and treat human diseases related to metabolic dysfunction. Several synthetic molecules have been shown to inhibit the constitutive transcriptional activity of ERRα including compound A ([@B133]), XCT790, compound 29 (C29), and compound 50 (C50) that act as ERRα inverse agonists ([@B100], [@B114], [@B134]). Consistent with the results obtained using ERRα-null mice as a model, treatment with the inverse agonist C29 led to normalized insulin and circulating triglyceride levels, improved insulin sensitivity and glucose tolerance in diet-induced obesity (DIO) mouse models as well as an overt diabetic rat model ([@B100]). Chronic administration of C50 showed similar beneficial effects in two murine models of obesity and insulin resistance ([@B114]). Interestingly, C29 and C50 modulate ERRα\'s activity in a tissue-specific manner. Given the beneficial effects of ERRα in skeletal muscle, inhibition of ERRα in the liver or adipose tissue, accompanied by its activation in skeletal muscle would be a therapeutic avenue for the treatment of the metabolic syndrome. As discussed above, ERRα is subject to the regulation by PTMs, which affect ERRα protein stability or physical interaction with coregulators. Future drug discovery relating to the specific regulation of ERRα transcriptional activity through PTMs would require further exploration of the physiologic, nutrient and hormonal cues that lead to the specific PTMs of ERRα and their relevant effects on cellular metabolism. Known compounds such as kinase inhibitors may exert their beneficial effects in the treatment of the metabolic syndrome via alteration of ERRα transcriptional activity either directly or indirectly. It is reasonable to hypothesize that combination therapies might lead to the desired beneficial anti-diabetic outcome but with less unwanted adverse effects. While it is clear that targeting ERRα activity in the liver may have therapeutic potential, future research and drug development will have to take into account the roles played by the three ERRs in the complex interplay between all metabolic tissues in the development of the metabolic syndrome and associated ailments.
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